Seres Therapeutics (MCRB) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic focus and recent developments

• Achieved FDA approval for VOWST, the first oral live microbiome therapeutic, and sold majority rights to Nestlé Health Science, securing $100M upfront, $15M equity investment, $60M prepaid milestone, and up to $275M in future milestones, extending cash runway into Q1 2026 and retiring debt.

• SER-155, the lead program, received FDA Breakthrough Therapy Designation in December 2024 and demonstrated strong efficacy and safety in phase 1b for preventing infections in allo-HSCT patients.

• Company is prioritizing SER-155 advancement, focusing on regulatory engagement, manufacturing readiness, and strategic partnerships for global reach and expansion to additional high-risk patient populations.

• SER-147 is advancing toward IND readiness for infection prevention in chronic liver disease, supported by promising preclinical data.

• Financial position is strengthened by the VOWST transaction, with $31M cash at year-end 2024 and additional milestone payments expected in 2025.

Clinical and scientific insights

• SER-155 showed a 77% relative risk reduction in bloodstream infections versus placebo, with significant reductions in antibiotic exposure and improved gut barrier integrity.

• New biomarker data indicate reduced fecal albumin and pro-inflammatory markers, supporting the mechanism of action and durability of bacterial engraftment.

• SER-155’s oral delivery and outpatient administration are positively received by payers and healthcare providers, with potential for broad adoption in standard care.

• Indication expansion for SER-155 could increase the addressable population tenfold, including autologous HSCT and broader oncology settings.

• Expansion opportunities include auto-HSCT, other blood cancers, and chronic liver disease, with SER-147 in IND-enabling stages targeting infections in cirrhosis patients.

Industry analysis and market opportunity

• High unmet need for infection prophylaxis in allo-HSCT, with about 40,000 annual transplants worldwide and significant incremental costs from infections.

• Market research indicates oral administration and robust efficacy profile of SER-155 are highly valued by payers, supporting favorable reimbursement outlook.

• VOWST approval and sale validate the live biotherapeutics platform and provide financial resources for pipeline advancement.